About: Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.35 (-0.30%)
ALTNASDAQAltimmune Inc
Altimmune Inc share price
ALT price activity
Último preço
$ 3,350
Variação (24h)
-0,01 USD (-0,30%)
Volume
3.07M
Volume (média 4 sem.)
-
Abertura
$ 3,35
Variação do dia
$ 3,29 - $ 3,43
Fechamento anterior
$ 3,36
Último negócio
09 Sep, 8:16 pm GMT+0
Atrasado
09 Sep, 8:16 pm GMT+0
ALT price performance
Atrasado
09 Sep, 8:16 pm GMT+0
quote.marketSignals